NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the results of a prospective, observational study published in Acta Paediatrica in which researchers from the Hospital ...
Masimo Corporation MASI recently announced the findings of a study published in Clinical Medicine Insights: Pediatrics, demonstrating the experience using the Masimo Rad-G Pulse Oximeter. The study ...
IRVINE, Calif., Sept. 3 Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, today announced that its Radical-7 and Rad-57 Pulse CO ...
Masimo SET ® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, 1 improve CCHD screening in newborns, 2 and, when used for continuous monitoring in ...
Masimo (NASDAQ: MASI) announced today that the United Arab Emirates (UAE) Ministry of Health & Prevention (MOHAP) is adopting a national screening protocol for critical congenital heart disease (CCHD) ...
BUSINESS WIRE )-- Masimo (NASDAQ: MASI) today announced the findings of a study published in Clinical Medicine Insights: Pediatrics in which Dr. Harish Kumar and colleagues at IPE Global in New Delhi, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results